GILEAD SCIENCES, INC. (GILD) vs VERTEX PHARMACEUTICALS INC / MA (VRTX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | GILD | VRTX |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $29.44B | $12B |
| Revenue growth (YoY) | ▲ 2.4% | ▲ 8.9% |
| Net income | $8.51B | $3.95B |
| Gross margin | 78.8% | 86.2% |
| Diluted EPS | $6.78 | $15.32 |
| Insider net (6 mo) | +385.1K sh • 18 sells • 0 buys | +809 sh • 14 sells • 0 buys |
| Institutional owners | 46 | 47 |
| Institutional value held | $98.74B | $86.39B |
| Next earnings (est.) | Around Oct 29, 2026 | Nov 2, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About GILEAD SCIENCES, INC. (GILD)
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, operating in more than 35 countries, dedicated to discovering, developing and delivering innovative medicines addressing unmet medical needs in virology, oncology… Read more →
About VERTEX PHARMACEUTICALS INC / MA (VRTX)
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing transformative medicines for people with serious diseases, concentrating on specialty markets. Read more →
Source: SEC EDGAR.